
Dulaglutide
Dulaglutide is a long-acting GLP-1 receptor agonist composed of two GLP-1 analog chains fused to an IgG4 Fc fragment. In research settings it’s used to study gl…
Half-life
Approximately ~120 hours (~5 days)
Delivery
Once-weekly subcutaneous injection (prefilled pen formats in clinical use; dose and device vary by study/protocol).
Suggested dosage
Not specified
Usage
Mechanism of action
Benefits (4)
- Improved fasting and postprandial glucose
- Reduced A1c in type 2 diabetes models
- Decreased appetite and body weight in study populations
- Potential cardiovascular risk-marker improvements
Side effects (6)
- Nausea, vomiting, diarrhea, or constipation
- Abdominal pain or decreased appetite
- Injection-site reactions
- Rare: pancreatitis, gallbladder disease
- Hypoglycemia when combined with insulin or sulfonylureas
- Boxed warning (rodent): thyroid C-cell tumors; contraindicated with personal/family history of MTC or MEN2 in clinical use contexts